Old Bladder Drug Shows Promise Against Devastating Mitochondrial Diseases
A common medication, typically prescribed for bladder incontinence, is emerging as a potential new weapon against debilitating mitochondrial diseases. Researchers have discovered that oxybutynin can enhance cellular energy production by promoting glycolysis, offering a novel therapeutic avenue for these genetic disorders that currently lack effective treatments.
Key Takeaways
- Oxybutynin, an established drug for bladder issues, shows potential in treating mitochondrial diseases.
- The drug works by boosting cellular glycolysis, a backup energy pathway, rather than directly fixing damaged mitochondria.
- Studies on mouse and human muscle stem cells demonstrate improved muscle repair and growth.
- The findings offer hope for repurposing an inexpensive, FDA-approved drug for rare genetic conditions.
A Surprising New Role for Oxybutynin
Mitochondrial diseases, affecting approximately one in every 5,000 people, often strike children and lead to severe muscle weakness, neurological decline, and heart problems, with no known cures. A team at Cornell University explored a novel approach by screening thousands of small molecules for their potential to treat mitochondrial dysfunction directly within muscle stem cells.
Enhancing Cellular Energy Pathways
Among the molecules tested, oxybutynin stood out. The research revealed that the drug doesn't repair the damaged mitochondria themselves. Instead, it prompts cells to rely more heavily on glycolysis, a rapid process of breaking down glucose for energy. This backup system provides sufficient power to revive cellular growth and repair, particularly in muscle stem cells responsible for muscle maintenance and development.
Promising Results in Stem Cell Studies
Experiments conducted on both mouse and human muscle stem cells demonstrated that oxybutynin treatment significantly improved their ability to multiply and form muscle fibers. These treated cells exhibited enhanced strength, produced more muscle fibers, and maintained higher energy levels compared to untreated cells. The mechanism involves oxybutynin interacting with proteins involved in RNA processing, leading to increased transport of amino acids and glucose into the cells.
Towards Clinical Application
While human clinical trials for mitochondrial disease have not yet begun, the findings are encouraging. Collaborations are underway with the Children's Hospital of Philadelphia, where researchers are testing oxybutynin on cells from children with mitochondrial diseases. The potential to repurpose an existing, inexpensive, and FDA-approved drug like oxybutynin could significantly accelerate the development of new therapies, bypassing years of costly research and offering a much-needed lifeline to patients and their families.
Sources
- Decades-old drug deployed in fight against mitochondrial diseases, Cornell Chronicle.
